Cargando…
A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma.
The aim of the protocol was to evaluate the side-effects induced by repeated tumour-infiltrating lymphocyte (TIL) infusions in patients with metastatic melanoma (MM). Patients were to receive four TIL infusions at given intervals: every 3 weeks (two patients), every 2 weeks (3 patients) and weekly (...
Autores principales: | Ravaud, A., Legrand, E., Delaunay, M. M., Bussières, E., Coulon, V., Cany, L., Huet, S., Verdier, D., Kind, M., Chomy, F. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033579/ https://www.ncbi.nlm.nih.gov/pubmed/7530984 |
Ejemplares similares
-
Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs)
por: Nguyen, Linh T., et al.
Publicado: (2010) -
Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer
por: Poch, Michael, et al.
Publicado: (2018) -
Clinical Significance of Tumour-Infiltrating B Lymphocytes (TIL-Bs) in Breast Cancer: A Systematic Literature Review
por: Lam, Brian M., et al.
Publicado: (2023) -
Genetically engineered lymphocytes in metastatic melanoma: TIL 1383I TCR transduced T-cells are detectable after infusion
por: Regan, Courtney, et al.
Publicado: (2013) -
Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy
por: Chen, Jie Qing, et al.
Publicado: (2013)